# A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease

> **NCT04102111** · PHASE2 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 48 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** JNJ-67864238
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04102111
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-23
- **Primary completion:** 2021-11-17
- **Final completion:** 2021-12-22
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** IAC completed review of futility analysis data \& determined that futility criteria were met. As a result, Janssen made decision to stop trial immediately.
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04102111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04102111, "A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04102111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*